For Aleksander Doba, pitting himself against the wide-open sea — storms, sunstroke, monotony, hunger and loneliness — was a way to feel alive in old age. Today, listen to the story of a man who paddled toward the existential crisis that is life and crossed the Atlantic alone in a kayak. Three times.Mr. Doba died on Feb. 22 on the summit of Mount Kilimanjaro in Tanzania, Africa. He was 74.This story was written by Elizabeth Weil and recorded by Audm. To hear more audio stories from publications like The New York Times, download Audm for iPhone or Android.
Unlock full access to New York Times podcasts and explore everything from politics to pop culture. Subscribe today at nytimes.com/podcasts or on Apple Podcasts and Spotify.

Nachrichten
The Daily Folgen
This is what the news should sound like. The biggest stories of our time, told by the best journalists in the world. Hosted by Michael Barbaro, Rachel Abrams and Natalie Kitroeff. Twenty minutes a day, five days a week, ready by 6 a.m. Unlock full access to New York Times podcasts and explore everything from politics to pop culture. Subscribe today at nytimes.com/podcasts or on Apple Podcasts and Spotify. Also, for more podcasts and narrated articles, download The New York Times app at nytimes.com/app.
Folgen von The Daily
2600 Folgen
-
Folge vom 11.07.2021From The Sunday Read Archives: ‘Alone at Sea’
-
Folge vom 09.07.2021The Assassination of Haiti’s PresidentEarly on Wednesday morning, a group of men killed President Jovenel Moïse of Haiti in his residence on the outskirts of the capital, Port-au-Prince.It was a brazen act. Very rarely is a nation’s leader killed in at home.What does the attack means for Haiti’s future?Guest: Maria Abi-Habib, bureau chief for Mexico, Central America and the Caribbean for The New York Times. Sign up here to get The Daily in your inbox each morning. And for an exclusive look at how the biggest stories on our show come together, subscribe to our newsletter. Background reading: The assassination of Mr. Moïse has rocked his nation, stoking fear and confusion about what is to come. Here is what we know and don’t know.The killing has left a political void and deepened the turmoil and violence that has gripped Haiti for months, threatening to tip one of the world’s most troubled nations further into lawlessness.For more information on today’s episode, visit nytimes.com/thedaily. Transcripts of each episode will be made available by the next workday. Unlock full access to New York Times podcasts and explore everything from politics to pop culture. Subscribe today at nytimes.com/podcasts or on Apple Podcasts and Spotify.
-
Folge vom 08.07.2021The End of America’s 20-Year WarAfter a 20-year war, the United States has effectively ended its operations in Afghanistan with little fanfare.In recent weeks, the Americans have quietly vacated their sprawling military bases in the nation, and without giving Afghan security forces prior notice.What does this withdrawal look like on the ground?Guest: Thomas Gibbons-Neff, a correspondent in the Kabul bureau for The New York Times. Sign up here to get The Daily in your inbox each morning. And for an exclusive look at how the biggest stories on our show come together, subscribe to our newsletter. Background reading: The Americans have handed over Bagram Air Base — once the military’s nerve center — to the Afghans, effectively ending operations.Just a mile from the base, where U.S. forces departed on Thursday, shops sell items left over from two decades of fighting. Each one tells a story.For more information on today’s episode, visit nytimes.com/thedaily. Transcripts of each episode will be made available by the next workday. Unlock full access to New York Times podcasts and explore everything from politics to pop culture. Subscribe today at nytimes.com/podcasts or on Apple Podcasts and Spotify.
-
Folge vom 07.07.2021'Some Hope Is Better Than Having No Hope'When the F.D.A. approved the drug Aduhelm, the first Alzheimer’s treatment to receive the agency’s endorsement in almost two decades, it gave hope to many.But the decision was contentious; some experts say there’s not enough evidence that the treatment can address cognitive symptoms.What is the story behind this new drug?Guest: Pam Belluck, a health and science writer for The New York Times. Sign up here to get The Daily in your inbox each morning. And for an exclusive look at how the biggest stories on our show come together, subscribe to our newsletter. Background reading: Aduhelm, also known as aducanumab, was approved despite opposition from the F.D.A.’s independent advisory committee and some Alzheimer’s experts.Even those who supported the F.D.A.’s approval have said that authorizing it for anyone with the disease is much too broad.For more information on today’s episode, visit nytimes.com/thedaily. Transcripts of each episode will be made available by the next workday. Unlock full access to New York Times podcasts and explore everything from politics to pop culture. Subscribe today at nytimes.com/podcasts or on Apple Podcasts and Spotify.